Citation Impact
Citing Papers
Practice Parameter: Prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based review) [RETIRED]
2006
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
2003 Standout
Threshold-free high-power methods for the ontological analysis of genome-wide gene-expression studies
2007
Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin
2004 StandoutNobel
No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec™/Glivec®)
2003
Quantification of mRNA using real-time RT-PCR
2006 Standout
The Transcription Factor Myc Controls Metabolic Reprogramming upon T Lymphocyte Activation
2011 Standout
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Chronic myelogenous leukemia
2001
Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia
2003
Chromatin structural elements and chromosomal translocations in leukemia
2006
Molecular monitoring of BCR–ABL as a guide to clinical management in chronic myeloid leukaemia
2005
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
Distribution and Biological Activities of the Flavonoid Luteolin
2008 Standout
Origins of chromosome translocations in childhood leukaemia
2003
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
2006 Standout
High-Resolution Profiling of Histone Methylations in the Human Genome
2007 Standout
Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction
2012 Standout
Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials
2004
Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects
2007
Dynamics of chronic myeloid leukaemia
2005 Nature
Anticancer activities of histone deacetylase inhibitors
2006 Standout
Detection of pathogenic Leptospira spp. through TaqMan polymerase chain reaction targeting the LipL32 gene
2009 Standout
Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function
2004 StandoutNobel
The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)
2011
Targeting cancer with small molecule kinase inhibitors
2008 Standout
Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists
2008 Standout
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
2002
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
2004
Chemotherapy and the war on cancer
2005 Standout
Detection of minimal residual disease
2001
European Resuscitation Council Guidelines for Resuscitation 2010 Section 4. Adult advanced life support
2010 Standout
Hematopoietic Stem-Cell Transplantation
2006 Standout
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
2005 Standout
Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program
2003
Virus target cell conditioning model to explain some epidemiologic characteristics of childhood leukemias and lymphomas
2005 StandoutNobel
Neutrophils, from Marrow to Microbes
2010 Standout
Chronic Eosinophilic Leukemias and the Myeloproliferative Variant of the Hypereosinophilic Syndrome
2007
Basic principles of real-time quantitative PCR
2005
PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification
2009
Neuroblastoma
2007 Standout
8p11 myeloproliferative syndrome: a review
2010
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
Liposomes as nanomedical devices
2015 Standout
Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative
2007 StandoutNobel
Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron
2009 Standout
Quantitative real-time PCR for cancer detection: the lymphoma case
2005
DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukemia
2005
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
An Overview of Real-Time Quantitative PCR: Applications to Quantify Cytokine Gene Expression
2001
Cancer as an evolutionary and ecological process
2006 Standout
Five years since the discovery of FIP1L1–PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias
2008
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
2006
IgE, mast cells, basophils, and eosinophils
2010 Standout
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
2001 Standout
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
The Fibroblast Growth Factor signaling pathway
2015 Standout
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Citrus polymethoxyflavones attenuate metabolic syndrome by regulating gut microbiome and amino acid metabolism
2020 Standout
Tumour stem cells and drug resistance
2005 Standout
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
2004
Nonimmunoglobulin target loci of activation-induced cytidine deaminase (AID) share unique features with immunoglobulin genes
2012 StandoutNobel
Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis
2005
Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems
2002 Standout
Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl
2004
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
2009 Standout
Part 9: Post–Cardiac Arrest Care
2010 Standout
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
2004 StandoutScience
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML
2006
Granulocyte inducer C/EBPα inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions
2002
Part 8: Post–Cardiac Arrest Care
2015 Standout
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
2006 Standout
Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR.
2001
Large-scale analysis of the human and mouse transcriptomes
2002 StandoutNobel
Minimal residual disease levels assessed by NPM1 mutation–specific RQ-PCR provide important prognostic information in AML
2009
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
2011
Works of A Weißer being referenced
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer
2004
Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia
2002
The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1
2005
Detection and quantification of residual disease in chronic myelogenous leukemia
2000
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α
2002
Treatment concepts of acute promyelocytic leukemia
2005
Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission
2003
Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR
1999
Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis
2006
Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes
2000
Treatment of a Patient with Advanced Esophageal Cancer with a Combination of Mitomycin C and Capecitabine: Activation of the Thymidine Phosphorylase as Active Principle?
2003